Baudax Bio Inc BXRXQ

Healthcare

Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.

PINL:BXRXQ - Post by User

Baudax Bio Inc

<< Previous

Bullboard Posts

Next >>

Post by Subchimes1on May 15, 2020 11:07am

172 Views

Post# 31033356

Institutions are on board!

Looks like institutions, are establishing positions, and raising price targets. This is looking very promising, would be nice to see a distribution agreement for Europe, Asia, Africa, Australia, or South America, even Canada would be nice to cement our position in the world. We got Amerca covered. Never sell a climbing stock, and always wise to average up, as oppose to averaging down.

<< Previous

Bullboard Posts

Next >>

Catch up with companies that got a Stanley Cup Playoffs boost